Paper16640337
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
Uehling DE and 16 others. J Med Chem, 2006. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. Papers, record 16640337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16640337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenergic beta-3 Receptor Agonists | Major topic |
| Aniline Compounds | Major topic |
| Ethanolamine | Major topic |
| Receptors, Adrenergic, beta-3 | Major topic |
| Animals | |
| Blood Glucose | |
| Cell Line | |
| Cricetinae | |
| Cyclic AMP | |
| Dogs | |
| Glycosylation | |
| Hemoglobins | |
| Humans | |
| Male | |
| Mice | |
| Molecular Structure | |
| Structure-Activity Relationship |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41292352 | A Versatile System of Solvent, Catalyst, and Ligand for Challenging Biphenyl Synthesis Through Suzuki-Miyaura Reactions. | Chemistry | 2025 | https://conductscience.org/library/papers/41292352 | PubMed |
| 38872059 | Adrenoceptor Expression and Function in the Endocrine Pancreas. | Handb Exp Pharmacol | 2024 | https://conductscience.org/library/papers/38872059 | PubMed |
| 38136585 | Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes? | Biomolecules | 2023 | https://conductscience.org/library/papers/38136585 | PubMed |
| 37792048 | In silico identification of a biarylamine acting as agonist at human β3 adrenoceptors and exerting BRL37344-like effects on mouse metabolism. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/37792048 | PubMed |
| 37656760 | Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. | PLoS One | 2023 | https://conductscience.org/library/papers/37656760 | PubMed |
| 33643052 | The Role of Periprostatic Adipose Tissue on Prostate Function in Vascular-Related Disorders. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33643052 | PubMed |
| 31263412 | Desensitization of cAMP Accumulation via Human β3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/31263412 | PubMed |
| 30868554 | β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions? | Br J Pharmacol | 2019 | https://conductscience.org/library/papers/30868554 | PubMed |
| 23263450 | Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. | Naunyn Schmiedebergs Arch Pharmacol | 2013 | https://conductscience.org/library/papers/23263450 | PubMed |
| 21626288 | A classification study of human β₃-adrenergic receptor agonists using BCUT descriptors. | Mol Divers | 2011 | https://conductscience.org/library/papers/21626288 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16640337
GET https://conductscience.org/api/papers/v1/16640337/authors